Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Thyroid Neoplasms × Ropivacaine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pain, Postoperative 16 Breast Neoplasms 15 Pain 8 Agnosia 6 Prostatic Neoplasms 5 Lung Neoplasms 5 Neoplasms 4 Stomach Neoplasms 3 Colonic Neoplasms 3 Supratentorial Neoplasms 2 Postoperative Complications 2 Colorectal Neoplasms 2 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Sleep Deprivation 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Pancreatic Ductal Adenocarcinoma 1 Pain, Intractable 1 Ovarian Cysts 1 Oropharyngeal Neoplasms 1 Neuroblastoma 1 Neoplasm Metastasis 1 Meningioma 1 Malignant Neoplasms of Male Genital Organs 1 Liver Neoplasms 1 Liver Diseases 1 Kidney Neoplasms 1 Intraoperative Complications 1 Head and Neck Neoplasms 1

Interventions

Iodine-131 14 lenvatinib 11 Magnetic Resonance Spectroscopy 10 trametinib 9 Thyrotropin Alfa 9 Sorafenib 9 vandetanib 8 pembrolizumab 8 Paclitaxel 8 dabrafenib 7 Thyroxine 7 selpercatinib 6 Surgical Procedures, Operative 6 Sunitinib 6 Everolimus 6 pazopanib 5 cabozantinib 5 Vemurafenib 5 Saline Solution 5 Cyclophosphamide 5 anlotinib 4 Triiodothyronine 4 Thyroidectomy 4 Radiofrequency Ablation 4 Nivolumab 4 Fluorodeoxyglucose F18 4 Docetaxel 4 Dexmedetomidine 4 fosbretabulin 3 durvalumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02112370 2017-08-04

REBT

Seoul National University Hospital

Phase 3 Completed

148 enrolled 17 charts

Goiter, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡